$90.00 - $90.00
Biotin-[Tyr0]-Orexin B is a biotinylated derivative of rodent Orexin B containing an additional N-terminal Tyr residue. The construct combines a streptavidin-compatible affinity handle with the complete mouse/rat Orexin B sequence.
Product Information
| Property | Specification |
|---|---|
| Sequence | Biotin-Tyr-Arg-Pro-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Asn-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH₂ |
| One-Letter Sequence | Biotin-YRPGPPGLQGRLQRLLQANGNHAAGILTM-NH₂ |
| Peptide Backbone Length | 29 residues including Tyr0 |
| Molecular Formula | C145H238N48O38S2 |
| Molecular Weight | Approximately 3325.9 Da |
| Modification | N-terminal biotin with added Tyr0 |
| Primary Use | Affinity capture and ligand-interaction studies |
Tyr0 Creates a Defined Labeling Extension
The construct does not attach biotin directly to the native Arg1 residue. Instead, an additional Tyr is placed before the endogenous rodent sequence and biotin is introduced at the extended N-terminus.
This architecture provides a defined tag position while retaining the complete native Orexin B backbone downstream.
Streptavidin-Based Applications
Potential uses include immobilized ligand experiments, affinity capture, receptor-interaction studies and assay development using streptavidin or avidin-family reagents.
We recommend validating receptor activity against unlabeled rodent Orexin B rather than assuming identical potency, because the Tyr0-biotin extension changes the N-terminal chemistry and molecular size.
Frequently Asked Questions
Is Tyr0 part of native rodent Orexin B?
No. Tyr0 is an added residue preceding the native Arg1 sequence.
Does the biotinylated construct necessarily have the same receptor potency as Orexin B?
No. Quantitative pharmacology should be measured experimentally.